Key result
High-efficacy disease-modifying treatments for relapsing-remitting multiple sclerosis offer improved efficacy but present complex therapeutic profiles that may negatively impact patient adherence.
Why the study?
Adherence to DMDs is often suboptimal in relapsing-remitting multiple sclerosis, creating a need to understand how the complex therapeutic and administration profiles of newer high-efficacy DMDs interact with treatment barriers to support adherence.
Understanding the complex therapeutic profiles of newer high-efficacy DMDs is necessary to support optimal adherence in relapsing-remitting multiple sclerosis.
The number of disease-modifying treatments (DMDs) for relapsing-remitting multiple sclerosis has increased. DMDs differ not only in their efficacy and safety/tolerability, but also in the treatment burden of, associated with their initiation, route/frequency of administration, maintenance treatment and monitoring. High-efficacy DMDs bring the prospect of improved suppression of relapses and progression of disability, but may have serious safety issues, and burdensome long-term monitoring. Studies of patient preferences in this area have focused on side effects, efficacy and route of administration. Adherence to DMDs is often suboptimal in relapsing-remitting multiple sclerosis and there is a need to understand more about how the complex therapeutic and administration profiles of newer DMDs interact with these barriers to support optimal adherence to therapy.
No takes yet. Share an insight, caveat, or question.
Inshasi et al. (2020) conducted a review in relapsing-remitting multiple sclerosis. High-efficacy disease-modifying treatments (DMDs) was evaluated. High-efficacy disease-modifying treatments for relapsing-remitting multiple sclerosis offer improved efficacy but present complex therapeutic profiles that may negatively impact patient adherence.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: